Partial
Mostly Aligned
Patient Risk:
Low
Summary
Most clinical/product descriptive claims are consistent with the provided label excerpts (indication, formulation, route, active ingredient). However, the response makes claims about pricing/patent databases and savings programs that are not supported by the provided FDA label excerpts; these become unsupported and materially reduce alignment.
Category Scores
Accurate Statements
Xyosted is a brand-name prescription medication used for testosterone replacement therapy in adult men who have low testosterone levels.
Indications and Usage: XYOSTED is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Xyosted is administered via subcutaneous injection.
Dosage and Administration: starting dose is administered subcutaneously; Administration instructions: for subcutaneous injection in the abdominal region only.
The active ingredient in Xyosted is testosterone enanthate.
Drug and active ingredient(s) section provided by user: XYOSTED (testosterone enanthate) injection; Dosage Forms and Strengths: solution containing testosterone enanthate.
Unsupported Statements
A list price of $2,377.40 is indicated for one 3-month supply of Xyosted.
No pricing or supply-duration/list price information is present in the provided FDA label excerpts.
Savings programs may be available that could reduce out-of-pocket expenses for eligible patients.
No information about savings programs, copay assistance, or out-of-pocket reduction appears in the provided FDA label excerpts.
The actual amount paid by patients with insurance depends on their specific plan, deductible, and copay.
No information about patient insurance/cost-sharing determinants is present in the provided FDA label excerpts.
Specific patent expiry information for Xyosted would need to be consulted through a patent database such as DrugPatentWatch.com.
No patent expiry or guidance to consult a patent database is present in the provided FDA label excerpts.
Contradictions
Important Omissions
No label-required prescribing details were provided regarding diagnosis confirmation (e.g., morning serum testosterone on two separate days), starting dose (75 mg once weekly), titration criteria, or key administration precautions (abdominal region only; avoid intramuscular/intravascular; inspect for cloudiness/particles; do not use if seal broken).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported non-label claims relate to pricing/patents/savings programs rather than direct clinical risk. The clinical descriptive claims (indication, active ingredient, subcutaneous route) align with provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Inclusion of pricing/patent/savings-program statements not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to what is present in the FDA label excerpts (e.g., indication, testosterone replacement therapy in adult males, testosterone enanthate, subcutaneous abdominal administration) and remove or qualify non-label information such as list price, savings programs, and patent database guidance unless supported by label or other authoritative sources.